ITM-91 by ITM Isotope Technologies Munich for Metastatic Colorectal Cancer: Likelihood of Approval

ITM-91 is under clinical development by ITM Isotope Technologies Munich and currently in Phase II for Metastatic Colorectal Cancer.

What to know about concerns raised about compounded versions of Novo Nordisk’s Wegovy

As demand for Ozempic and Wegovy surges, a little-noticed warning about the medicines was issued recently by regulators. In late May, the Food and Drug

August 10, 2023

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

There are a lot of reasons why updated data on Pfizer’s Lorbrena, a treatment for non-small cell lung cancer, might not seem to be a

May 31, 2024

Bristol Myers, Cellares sign global CAR-T deal as biopharma companies look to diversify manufacturing partners

Cellares has inked its first international deal with Bristol Myers Squibb, with the cell therapy manufacturer noting it is going through “tremendous tailwinds” from the

April 23, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.